Efecto de ß-Bloqueo sobre la Mortalidad

IC Dosis Efectos

Estudio Farmaco Severidad (mg/day) Mortalidad

US Carvedilol1 Carvedilol Ligera/ 6.25 to 25* ?65% mortalidad†

moderada BID (P=0.0001)

CIBIS-II2 Bisoprolol† Moderada/ 10 QD ?34% mortalidad

severa (Pɘ.0001)

MERIT-HF3 Metoprolol Ligera/ 200 QD ?34% mortalidad

succinate moderada (P=0.0062)

COPERNICUS4 Carvedilol Severa 25 BID ?35% mortalidad

(P=0.0014)

*50 mg BID if ᢍ kg.

†Not a planned endpoint.

1. Packer M et al. N Engl J Med. 1996;334:1349-1355.

2. CIBIS II Investigators and Committee. Lancet. 1999;353:9-13.

3. MERIT-HF Study Group. Lancet. 1999;353:2001-2007.

4. Packer M et al. N Engl J Med. 2001;344:1651-1658.

Diapositiva anterior

Diapositiva siguiente

Ir a la primera diapositiva

Ver versión gráfica

• The number of HF patients studied with ?-blockade actually exceeds the number of HF patients studied with ACE inhibition. ?-blockers have been evaluated in more than 10,000 HF patients in over 20 published clinical trials.1

• Only metoprolol succinate and carvedilol are approved for treatment in heart failure.

• Generic metoprolol and atenolol have not been proven effective in heart failure. (Please note: generic atenolol and metoprolol are not described on this slide.)